Windward Bio prices $175M IPO and adds $50M from Sanofi to chase Tezspire
The Basel immunology company sold about 10.3 million shares at $17, and Sanofi is buying $50 million more in a side placement. Its lead drug targets TSLP, the same protein as AstraZeneca and Amgen's asthma drug Tezspire.

- Amount
- $175M
- Type
- IPO
- Company
- Windward Bio
- Sector
- Biotech
- Announced
- Nov. 12, 2026
Windward Bio is about two years old and is now a public company. The Basel, Switzerland, drug developer said Nov. 12 that it priced its initial public offering of 10,294,117 shares at $17 each, raising about $175 million before fees, with trading set to begin Nov. 13 on the Nasdaq Global Select Market under the ticker WWB.
Sanofi is adding to its position alongside the offering. A Sanofi affiliate agreed to buy 1,532,691 shares plus pre-funded warrants for another 1,408,485 shares at the IPO price, for $50 million in total, in a concurrent private placement. Counting that sale, Windward expects gross proceeds of $225 million before underwriting discounts and any extra shares the banks buy.
Why it matters: Windward is asking public investors to fund a challenge to an established asthma biologic using two drugs licensed from Chinese companies. BioPharma Dive counted the deal as the biotech sector's 30th IPO of 2026 and the ninth this year by a developer of immune drugs, a pace it said tops every year since 2018.
The terms
The $17 price was in line with the projections Windward set earlier in the week, BioPharma Dive reported. Underwriters have 30 days to buy up to 1,544,117 more shares. The joint book-running managers are Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank. Both the IPO and the Sanofi placement were scheduled to close Nov. 16; the placement depends on the IPO closing, but the IPO does not depend on the placement, according to the announcement.
Before the offering, Windward had raised $365 million in venture funding, BioPharma Dive reported. The company did not give a market value in its pricing announcement.
The deal follows another immunology listing two weeks earlier. Bambusa Therapeutics, a Boston developer of long-acting bispecific antibodies for inflammatory diseases, priced its Nasdaq IPO at $16 a share on Oct. 29.
The pipeline
Windward describes itself as a clinical-stage company making antibody drugs, which it calls ultra-long-acting, for serious respiratory and skin diseases. Its lead drug, WIN378, is aimed at TSLP, an inflammatory protein. Tezspire, from AstraZeneca and Amgen, works on the same target and brought the two companies nearly $2 billion combined last year, according to BioPharma Dive. Tezspire is taken monthly; Windward said in a regulatory filing that WIN378 could be given as rarely as twice a year, the outlet reported.
WIN378 is in a Phase 2/3 trial in severe, uncontrolled asthma, and the Phase 3 portion started in September, with results expected in 2027. A mid-stage study in chronic obstructive pulmonary disease began in June and is also due to produce data in 2027. A second drug, WIN027, is a bispecific antibody that hits both TSLP and IL-13; Windward expects Phase 1 results in healthy volunteers in the first half of 2027.
Both programs came from China. WIN378 was licensed from Kelun Biotech, which developed it with Harbour BioMed, and WIN027 came from Qyuns Therapeutics. Windward handed over $70 million in upfront cash and stock for the pair and could owe as much as $1.6 billion more if development and sales milestones are met, BioPharma Dive reported.
What to watch
The TSLP field is crowded. AbbVie, Pfizer, Upstream Bio and Generate Biomedicines are among the companies pursuing the same target, the outlet noted. The listing also went ahead as Rezera, a Boston biotech, postponed its own offering, citing market conditions, according to IPOScoop as reported by BioPharma Dive.
Windward's next disclosed milestones are the WIN027 Phase 1 data in the first half of 2027 and the asthma and COPD readouts for WIN378 expected that year.



